10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
US pharma major Eli Lilly has announced executive leadership changes and the creation of neuroscience and immunology business units. Effective September 5, Lilly Bio-Medicines will split into two business units: Lilly Neuroscience and Lilly Immunology. 18 August 2021
Californian immunotherapy company Gritstone Bio has received an investment of up to $20.6 million to take forward its next-generation coronavirus vaccine. 17 August 2021
The Russian government may expand the list of purchased high-priced drugs for its needs by beginning purchases of risdiplam – a drug for treatment of spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent 17 August 2021
The China National Medical Products Administration (NMPA) has further approved Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in pediatric patients. 17 August 2021
US privately-held biotech HiberCell today announced the acquisition of Genuity Science, a life science technology company – previously known as WuXi NextCODE and with Chinese backing - that provides world-leading genomics and multi-omic analytics bolstered by an advanced artificial intelligence (AI) and machine learning (ML) platform to illuminate the underlying cause of cancer and other diseases. 17 August 2021
German biopharma CureVac offered a couple of updates on its partnered programs as it presented its quarterly financial results on Monday. 17 August 2021
US biotech giant Amgen has survived periods of accelerated erosion of legacy products before, but investors may not be aware of the erosion risk facing the company in 2025-2030, commented SVB Leerink Research analyst Geoffrey Porges. 17 August 2021
US biopharma Travere Therapeutics has announced positive top-line interim results from the ongoing pivotal Phase III PROTECT study of sparsentan, an investigational product candidate for the treatment of IgA nephropathy (IgAN). 17 August 2021
US biotech Incyte and China’s InnoCare have announced that Incyte and a subsidiary of InnoCare have entered into a collaboration and license agreement for the development and commercialization of tafasitamab, a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in Greater China. 17 August 2021
Japan’s largest drugmaker Takeda is currently developing multiple microbiome-targeting agents through a number of collaborations with innovative small companies. 17 August 2021
The government of Russia’s capital Moscow city, together with private investors will invest about 10 billion roubles ($137 million) in the construction of at least three large-scale pharmaceutical enterprises. 17 August 2021
Shares in British biotech Tiziana Life Sciences rose nearly 4% on Tuesday morning, after the firm announced positive results for its nasally-administered COVID-19 therapy foralumab. 17 August 2021
US biotech companies Exelixis and Invenra have expanded their discovery and licensing collaboration to include an additional 20 oncology targets. 16 August 2021
For many years, artificial intelligence (AI), in particular machine learning, have been touted as potentially transformational technologies for drug discovery and development. 16 August 2021
The US Food and Drug Administration (FDA) has amended the emergency use authorizations (EUAs) for certain COVID-19 vaccines to allow for the use of an additional in some immuno-compromised people. 16 August 2021
China’s Brii Biosciences has announced that the Phase III portion of the ACTIV-2 study evaluating its monoclonal neutralizing antibody combination therapy, BRII-196/BRII-198 has completed enrollment of 846 participants, in sites in the USA, Brazil, South Africa, Mexico and Argentina. 16 August 2021
Tokyo-based drugmaker Eisai has announced the Japanese launch of Tazverik Tablets 200mg (tazemetostat hydrobromide) for relapsed or refractory EZH2 gene mutation-positive follicular lymphoma, when standard treatment is not applicable. 16 August 2021
Lebrikizumab led to significant improvements with at least 75% skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), as measured by EASI, in ADvocate 1 and ADvocate 2 Phase III clinical trials announced today. 16 August 2021
Shares of USA-based oncology specialist Sesen Bio were all but annihilated on Friday, after the company revealed a major setback for its lead drug candidate, with the stock falling 57% by close of trading and a further 17.5% to $1.74 in after-hours trading. 16 August 2021
The US Food and Drug Administration has granted approval for Ticovac (tick-borne encephalitis (TBE) vaccine) for active immunization to prevent TBE in individuals 1 year of age and older. 16 August 2021
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Swiss generic and biosimilar medicines major Sandoz today announced that it has launched a generic paclitaxel formulation in the USA, the first generic to its reference medicine to be approved by the US Food and Drug Administration (FDA). 11 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024
Pfizer is to present initial findings from its CULTIVATE study of its sphingosine-1-phosphate (S1P) receptor modulator Velsipity (etrasimod) in Crohn’s disease (CD) at United European Gastroenterology Week 2024. 11 October 2024
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Switzerland-based KeyBioscience and US pharma major Eli Lilly have agreed to extend their collaboration on the development of dual amylin calcitonin receptor agonists (DACRA), a new class of potential treatments for obesity and related disorders. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
South Korea’s Samsung Bioepis has released its Fourth Quarter 2024 Biosimilar Market Report, marking the seventh-edition of the Quarterly Biosimilar Market Report in the United States. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024